ROBIN Oligometastasis (OligoMET) Center: Using Biomarker Correlates from a Prostate Cancer Clinical Trial to Improve Future Outcomes
Metastasis is the final common lethal pathway for most cancer patient's demise and once cancer has metastasized, it was generally considered incurable.
Category
  • Genitourinary
  • Oligometastatic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Techniques and Applications of Synthetic Images
In medical imaging and radiation oncology, image synthesis refers to generating a target image modality from a given source modality, for example, synthetic CT images from MRI simulations for treatment planning.
Category
  • General RO
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
The Journey of the Unknown Primary in the HPV Era: Evaluation, Treatment, Surveillance and Management of Oligometastatic Disease
Management of unknown primary head and neck squamous cell carcinomas has evolved as the incidence of p16 positive disease among head and neck cancer patients has increased.
Category
  • Head and Neck
  • Oligometastatic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Empowering Prostate Cancer Patients: Combating Misinformation and Optimizing Lifestyle
There are many evidence-based recommendations for nutrition and lifestyle in prostate cancer. Failure to counsel patients on nutrition and lifestyle leads to lower quality of care.
Category
  • Lifestyle Medicine
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Certificate of Attendance
Cost $99.00
Navigating the Complexities of Brain Metastases and Leptomeningeal Disease Management
The management of patients with brain metastases and leptomeningeal disease (LMD) presents complex clinical challenges requiring nuanced, evidence-based decision-making.
Category
  • Central Nervous System
  • Palliative Care
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Radiopharmaceutical Therapies: 177Lu-Dotatate and 177Lu-PSMA-617
Radiopharmaceutical therapies have been a breakthrough cancer treatment for tumors resistant to cytotoxic chemotherapy and many new radiopharmaceutical agents are in active development.
Category
  • Radiopharmaceutical Therapy
Format
  • Sessions onDemand
Credits
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Certificate of Attendance
Cost $149.00
New Tools for Formidable Foes: Strategies for Management of Unresected Soft Tissue Sarcomas
Some patients with soft tissue sarcomas may be inoperable due to medical comorbidity or might decline radical or amputative surgeries due to undesirable functional outcomes.
Category
  • Sarcoma
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
To Radiate or Not to Radiate? Updates to Management of Retroperitoneal Sarcoma
Retroperitoneal sarcomas (RPS), a rare subset of soft tissue sarcomas, account for 10-15% of these cases and are distinguished by their substantial size, infiltrative nature, and proximity to vital anatomical structures.
Category
  • Sarcoma
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Radiation as an Immune Catalyst: Techniques, Biology and Biomaterials for Enhancing Tumor Control
Increasing evidence has demonstrated the importance of immunomodulation on tumor control. Radiotherapy, specifically, can produce a multitude of local and systemic immunomodulatory effects, including reprogramming the tumor microenvironment and exposing tumor antigens via in situ vaccination.
Category
  • Radiobiology
  • Immunotherapy
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
ASTRO/KCA Joint Activity: Stereotactic Radiotherapy and Renal Cell Cancer, Overcoming Radioresistance and the Resistance to Radiate
This activity brings together an international panel and multidisciplinary expertise to discuss the emerging role of SABR to the primary in renal cell carcinoma (RCC).
Category
  • SBRT
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00

Pages